10Sep 2019

LA MUCOPOLYSACCHARIDOSE DE TYPE I: EFFICACITE DU TRAITEMENT ENZYMATIQUE SUBSTITUTIF PAR LA LARONIDASE CHEZ UN CAS.

  • Laboratoire de Biotechnologies et Valorisation des Ressources Naturelles, d?partement de biologie, universit? IBN ZOHR, Agadir, Maroc.
  • Laboratoire de Biologie Cellulaire et G?n?tique Mol?culaire d?partement de biologie, universit? IBN ZOHR, Agadir, Maroc.
  • Cabinet p?diatrique, Agadir, Maroc.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Mucopolusaccharidosis Type I (MPS I) is a lysosomal storage disease due to ?-L-iduronidase deficiency. Currently, the disease is treated buy the recombinant human ?-L-iduronidase (laronidase). This study evaluates the clinical outcome and quality of life, after two years of traitement by laronidase in a 10 years aged boy, late diagnosed at age 8 with Hurler-Scheie syndrome. The results of the ETS are encouraging. Indeed, this treatment was benefic since it has improved his quality of life; however it have not cure his disease.

  1. Guffon N. (2003): La mucopolysaccharidose de type I, Pr?sentation clinique et traitement actuel. M?dTh?rP?diatr; 6: 91-7.
  2. Neufeld E.F, Muenzer J, Scriver C.R, et al (2001): The Metabolic and Molecular Bases of Inherited Diseases. McGraw-Hill, New York; 3421:52.
  3. Muenzer J. (2004): The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. jpediatr; 144: 27-34.
  4. Summary of Product Characteristics (SPC). Aldurazyme 100 U/ml concentrates for solution for infusion, EMA, 2003.
  5. Kakkis ED, Muenzer J, Tiller GE, et al (2001): Enzyme-replacement therapy in mucopolysaccharidoses I. NEngl J Med; 344: 182-8.
  6. Cox-Brinkman J, Boelens J.J, Wraith J.E, et al (2006): Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant; 38:17-21.
  7. Chkioua L, Ferchichi S, Khedhiri S et al (2007): La mucopolysaccharidose de type I: strat?gie diagnostique en Tunisie. Ann BiolMolPratiquequotidienne; 65:175-9.
  8. Caillaud C. (2006): La mucopolysaccharidose de type I: traitements actuels. Dossier du CNHIM; 1152: 23.
  9. Wraith JE, Clarke LA, Beck M et al (2004): Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr; 144: 581-8.
  10. Wraith JE. (2005): The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert OpinPharmacother; 6: 489-506.
  11. Geiger R, Strasak A, Treml B et al (2007): Six-minute walk test in children and adolescents, J. Pediatr; 150: 395-399.
  12. Valayannopoulos V, Wijburg FA. (2011): Therapy for the mucopolysaccharidoses. Rheumatology; 50: 49-59.
  13. Kakkis ED, McEntee MF, Schmidtchen A et al (1996): Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. BiochemMol Med; 58: 156-67.
  14. Sifuentes M, Doroshow et al (2007): Afollow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Gent Me tab; 90(2): 171-80.
  15. Clarke L.A, Wraith J.E, Beck M et al (2009): Long-termefficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics; 123: 229-40.
  16. Tylki-Szymanska A, Marucha J, Jurecka A, et al (2010): Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis; 33:151-7.
  17. Muenzer J, Fisher A. (2004): Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med; 350: 1932-4.

[Fadoua Bouzid, Zahra Brakez, Ilham Benyamna, Abdelhamid Elmousadik, Bouchaib Jabir and Najat Alif. (2019); LA MUCOPOLYSACCHARIDOSE DE TYPE I: EFFICACITE DU TRAITEMENT ENZYMATIQUE SUBSTITUTIF PAR LA LARONIDASE CHEZ UN CAS. Int. J. of Adv. Res. 7 (Sep). 541-545] (ISSN 2320-5407). www.journalijar.com

BOUZID Fadoua
Laboratoire de Biotechnologies et Valorisation des Ressources Naturelles, département de biologie, université IBN ZOHR, Agadir, Maroc.

DOI:

Article DOI: 10.21474/IJAR01/9695      
DOI URL: https://dx.doi.org/10.21474/IJAR01/9695

Download Full Paper

Download PDF No. of Downloads: 26 | No. of Views: 81